423 related articles for article (PubMed ID: 29298116)
21. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations.
El Sissy FN; Wassef M; Faucon B; Salvan D; Nadaud S; Coulet F; Adle-Biassette H; Soubrier F; Bisdorff A; Eyries M
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):905-912. PubMed ID: 35238086
[TBL] [Abstract][Full Text] [Related]
23. Somatic
Peyre M; Miyagishima D; Bielle F; Chapon F; Sierant M; Venot Q; Lerond J; Marijon P; Abi-Jaoude S; Le Van T; Labreche K; Houlston R; Faisant M; Clémenceau S; Boch AL; Nouet A; Carpentier A; Boetto J; Louvi A; Kalamarides M
N Engl J Med; 2021 Sep; 385(11):996-1004. PubMed ID: 34496175
[TBL] [Abstract][Full Text] [Related]
24. KRAS/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis.
Bameri O; Salarzaei M; Parooie F
Interv Neuroradiol; 2021 Aug; 27(4):539-546. PubMed ID: 33401991
[TBL] [Abstract][Full Text] [Related]
25. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
26. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
27. A human model of arteriovenous malformation (AVM)-on-a-chip reproduces key disease hallmarks and enables drug testing in perfused human vessel networks.
Soon K; Li M; Wu R; Zhou A; Khosraviani N; Turner WD; Wythe JD; Fish JE; Nunes SS
Biomaterials; 2022 Sep; 288():121729. PubMed ID: 35999080
[TBL] [Abstract][Full Text] [Related]
28. Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Florian IA; Timiș TL; Ungureanu G; Florian IS; Bălașa A; Berindan-Neagoe I
Neurol Res; 2020 Dec; 42(12):1043-1054. PubMed ID: 32723034
[No Abstract] [Full Text] [Related]
29. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
31. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
[TBL] [Abstract][Full Text] [Related]
32. Endothelial k-RasV12 Expression Induces Capillary Deficiency Attributable to Marked Tube Network Expansion Coupled to Reduced Pericytes and Basement Membranes.
Sun Z; Kemp SS; Lin PK; Aguera KN; Davis GE
Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):205-222. PubMed ID: 34879709
[TBL] [Abstract][Full Text] [Related]
33. Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway.
Smits PJ; Konczyk DJ; Sudduth CL; Goss JA; Greene AK
Biochem Biophys Res Commun; 2020 Aug; 529(2):450-454. PubMed ID: 32703450
[TBL] [Abstract][Full Text] [Related]
34. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
[TBL] [Abstract][Full Text] [Related]
35. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy.
Al-Olabi L; Polubothu S; Dowsett K; Andrews KA; Stadnik P; Joseph AP; Knox R; Pittman A; Clark G; Baird W; Bulstrode N; Glover M; Gordon K; Hargrave D; Huson SM; Jacques TS; James G; Kondolf H; Kangesu L; Keppler-Noreuil KM; Khan A; Lindhurst MJ; Lipson M; Mansour S; O'Hara J; Mahon C; Mosica A; Moss C; Murthy A; Ong J; Parker VE; Rivière JB; Sapp JC; Sebire NJ; Shah R; Sivakumar B; Thomas A; Virasami A; Waelchli R; Zeng Z; Biesecker LG; Barnacle A; Topf M; Semple RK; Patton EE; Kinsler VA
J Clin Invest; 2018 Apr; 128(4):1496-1508. PubMed ID: 29461977
[TBL] [Abstract][Full Text] [Related]
36. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
37. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Biernacka A; Tsongalis PD; Peterson JD; de Abreu FB; Black CC; Gutmann EJ; Liu X; Tafe LJ; Amos CI; Tsongalis GJ
Cancer Genet; 2016 May; 209(5):195-8. PubMed ID: 27068338
[TBL] [Abstract][Full Text] [Related]
38. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
39. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
[TBL] [Abstract][Full Text] [Related]
40. Cancer-Associated Mutations in Endometriosis without Cancer.
Anglesio MS; Papadopoulos N; Ayhan A; Nazeran TM; Noë M; Horlings HM; Lum A; Jones S; Senz J; Seckin T; Ho J; Wu RC; Lac V; Ogawa H; Tessier-Cloutier B; Alhassan R; Wang A; Wang Y; Cohen JD; Wong F; Hasanovic A; Orr N; Zhang M; Popoli M; McMahon W; Wood LD; Mattox A; Allaire C; Segars J; Williams C; Tomasetti C; Boyd N; Kinzler KW; Gilks CB; Diaz L; Wang TL; Vogelstein B; Yong PJ; Huntsman DG; Shih IM
N Engl J Med; 2017 May; 376(19):1835-1848. PubMed ID: 28489996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
